Heart-lung transplantation for cystic fibrosis.

2: Outcome

B Whitehead, P Helms, M Goodwin, I Martin, J P Scott, R L Smyth, T W Higenbottam, J Wallwork, M Elliott, M de Leval

Abstract
From March 1988 to March 1990, 11 children with cystic fibrosis (age 5–15 years) underwent combined heart-lung transplantation at our institutes. Maintenance immunosuppresion consisted of cyclosporin and azathioprine with corticosteroids and antithymocyte globulin used perioperatively and during rejection episodes. Six patients (55%) survive from 1–23 months all of whom have improved life quality. Actuarial survival to 1 year was 55%. At six months after transplant, mean forced expiratory volume at one second was 73.5% of predicted normal, compared with 25% before transplant. There was one perioperative death, three late deaths associated with obliterative bronchiolitis at two, eight, and nine months, and one from mediastinitis at four months. Of the 15 children accepted for transplantation but not receiving grafts, 10 have died (eight within four months of being placed onto the transplant list).

Early postoperative problems included acute reversible rejection (n=10), meconium ileus equivalent (n=3), and pancreatitis (n=1). There was a high incidence of later pulmonary rejection with a mean of 5.7 episodes per patient in the first six months. Pulmonary infection occurred relatively infrequently, with Pseudomonas aeruginosa being the most common pathogen. Persistent diabetes mellitus requiring insulin occurred in four and systemic hypertension developed in one.

Heart-lung transplantation has been successfully used in the management of end stage respiratory disease in adults with cystic fibrosis.1 The early fears of disease recurrence and overwhelming sepsis in those transplanted have been allayed.2 This has encouraged the referral of paediatric patients with cystic fibrosis, who currently represent the largest group being assessed for transplantation at our institutes.3 We have described our experience with the assessment of patients referred for heart-lung transplantation in the first part of this review and now detail outcome in those transplanted.

Patients and methods
From March 1988 to March 1990, 11 children with cystic fibrosis (age 5–15 years, mean=12) including six boys and five girls, underwent combined heart-lung transplantation. Ten were performed at the Hospital for Sick Children, London and one at Papworth Hospital, Cambridge. All patients were severely incapacitated with end stage lung disease with a mean (SD) forced expiratory volume at one second as percentage of predicted normal (FEV1,%) of 25.0 (10.5). They all had a poor quality of life with a mean (SD) Shwachman-Kulczycki score of 33.3 (4.3) (table 1).

Donor organs were obtained from ABO blood group and cytomegalovirus antibody compatible patients who had sustained brain death. Size matching was by predicted donor total lung capacity together with direct comparison of chest radiographs of donor and recipient. Organ evaluation and procurement were performed as previously described.4 The recipient operation was timed to minimise total ischaemia to 240 minutes.

Perioperative immunosuppression comprised cyclosporin, azathioprine, corticosteroids, and antithymocyte globulin (Atgam-Upjohn or Lymphoglobuline-Merieux) (table 2). Maintenance treatment was with cyclosporin to achieve whole blood concentrations of 600–1000 μg/l (modified fluorescence polarisation assay, TDx method, Abbott Laboratories) and azathioprine (ensuring total white cell count did not fall

Table 1 Details of patients with cystic fibrosis receiving heart-lung transplantation

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Preoperative FEV1%</th>
<th>Prophylactic Shwachman-Kulczycki score</th>
<th>Wasting period (days)</th>
<th>Ileaeamic time (min)</th>
<th>Postoperative ventilation (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11–5</td>
<td>F</td>
<td>15</td>
<td>NA</td>
<td>170</td>
<td>184</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>14–0</td>
<td>M</td>
<td>21</td>
<td>30</td>
<td>13</td>
<td>179</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>14–2</td>
<td>M</td>
<td>18</td>
<td>32</td>
<td>143</td>
<td>170</td>
<td>28</td>
</tr>
<tr>
<td>4</td>
<td>9–5</td>
<td>M</td>
<td>23</td>
<td>34</td>
<td>7</td>
<td>250</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>9–7</td>
<td>M</td>
<td>19</td>
<td>35</td>
<td>174</td>
<td>170</td>
<td>19</td>
</tr>
<tr>
<td>6</td>
<td>5–8</td>
<td>F</td>
<td>15</td>
<td>34</td>
<td>34</td>
<td>98</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>8–1</td>
<td>F</td>
<td>36</td>
<td>42</td>
<td>230</td>
<td>210</td>
<td>36</td>
</tr>
<tr>
<td>8</td>
<td>14–2</td>
<td>M</td>
<td>31</td>
<td>36</td>
<td>73</td>
<td>239</td>
<td>27</td>
</tr>
<tr>
<td>9</td>
<td>11–2</td>
<td>M</td>
<td>39</td>
<td>36</td>
<td>59</td>
<td>151</td>
<td>14</td>
</tr>
<tr>
<td>10</td>
<td>14–2</td>
<td>F</td>
<td>43</td>
<td>34</td>
<td>85</td>
<td>96</td>
<td>8</td>
</tr>
<tr>
<td>11</td>
<td>15–5</td>
<td>M</td>
<td>11</td>
<td>27</td>
<td>54</td>
<td>204</td>
<td>102</td>
</tr>
</tbody>
</table>

Mean 12-0 25-0 33-3 98-8 176-5 29-5

NA, not applicable.
Heart-lung transplantation for cystic fibrosis.

Table 2: Immunosuppression for heart-lung transplantation in cystic fibrosis

<table>
<thead>
<tr>
<th>Preoperative</th>
<th>Perioperative</th>
<th>Postoperative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporin*</td>
<td>5–10 mg/kg</td>
<td>5–50 mg/kg/day</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>2 mg/kg</td>
<td>2 mg/kg/day</td>
</tr>
<tr>
<td>Methylprednisolone (intravenous)</td>
<td>10 mg/kg×2</td>
<td>0.5 mg/kg × 3</td>
</tr>
<tr>
<td>Antithymocyte globulin</td>
<td>—</td>
<td>0.5 mg/kg × 3</td>
</tr>
<tr>
<td>Oral prednisolone</td>
<td>—</td>
<td>0.5 mg/kg/day</td>
</tr>
</tbody>
</table>

*Cyclosporin administered via enteral route, together with pancreatic enzymes, three times daily.
†Dose adjusted to keep white cell count >5×10⁹/L.
‡Dose adjusted according to total T cell number.

below 5.0×10⁹/L). Corticosteroids were given during acute rejection episodes commencing with three daily doses of intravenous methylprednisolone (10 mg/kg/dose) followed by a reducing oral prednisolone course (starting at 1 mg/kg/day).

Initial postoperative management included early extubation and maintenance of a negative intrathoracic fluid balance to prevent pulmonary oedema. Histamine (H₂) receptor antagonists (ranitidine 4 mg/kg/day) and oral antacids were administered until full enteral feeding was achieved. Regular oral acetylcysteine (Fabrol sachets, Zyma), lactulose, and pancreatic enzymes (Pancrex V powder, Paines and Byrne or Creon capsules, Duphar) were given, the latter with both food and cyclosporin. If enteral energy intake was poor (less than 0.42 MJ/kg/day) by three to four days postoperatively, intravenous feeding was instigated.

Perioperative antibiotic prophylaxis consisted of flucloxacillin (100 mg/kg/day) together with either cefotaxime (100 mg/kg/day) or gentamicin (4 mg/kg/day with the dose adjusted to blood concentrations and renal function). In addition, appropriate antipseudomonal antibiotics (for example, ceftazidime 150 mg/kg/day) were administered for five to seven days if this organism had been grown from the excised trachea. Co-trimoxazole (sulphamethoxazole 20 mg and trimethoprim 4 mg/kg/day) was given after the first week as prophylaxis against Pseudomonas and the patient was herpes simplex virus antibody positive, acyclovir (200 mg/m²/8 hours) was administered over the first three postoperative months. An antifungal agent (nystatin suspension 100 000 units four times a day) was continued indefinitely.

Surveillance for pulmonary rejection and/or infection was by regular clinical examination, chest radiography,¹¹ spirometry,⁴ and when indicated, transbronchial biopsy.¹⁰ ¹¹ Patients were given portable microspirometers (Micro Medical) and twice daily FEV₁ and forced vital capacity measurements were recorded. If there was a fall in these values of greater than 10–15%, bronchoscopy, bronchoalveolar lavage, and transbronchial biopsies were performed. Bronchoalveolar lavage was used for bacterial and viral culture, and histopathological examination for evidence of rejection was performed on the transbronchial biopsy specimen.¹² A single biopsy sample was also sent to culture for opportunistic organisms. If rejection was present histologically, steroids were administered as above. Infections were treated according to culture.

Patients were discharged with their parents and siblings to a nearby family hostel after three to four weeks, where they remained for a further one to two weeks before their return home. Outpatient follow up was once a week for three months, twice a week to six months, and every three to four weeks thereafter. This included clinical assessment together with weight, blood pressure, urinalysis, and chest radiography being performed. Full blood count, concentrations of serum urea, electrolytes, creatinine, C reactive protein, cyclosporin, and liver function tests were routinely performed. Immunosuppression treatment was altered according to these results. Systemic hypertension was treated by calcium channel blockers (nifedipine 1–4 mg/kg/day). Persistent hyperglycaemia was managed with a twice daily regimen of insulin incorporating short- and longer-acting forms (Actrapid and Monotard, Novo Laboratories Ltd).

Results

The mean waiting period from acceptance onto the active waiting list to transplantation was 98±8 days (range 7–230 days). All grafts were procured distantly. Total mean (SD) organ ischaemic time was 176±5 (47±4) minutes. Early graft function was good in all except patient 7. Ventilatory support was required for a mean of 29.5 hours (range 6–102 hours) and all survivors were breathing spontaneously in air by the end of the first postoperative week (table 1). Of the 11 children who have received heart-lung transplantation, six (55%) survive from 1·5–23 months, all of whom have returned to age appropriate activities (fig 1). Although our

Figure I: Survival in months of 11 patients with cystic fibrosis after heart-lung transplantation. Patients who have died are indicated by a cross.

Figure 1: Survival in months of 11 patients with cystic fibrosis after heart-lung transplantation. Patients who have died are indicated by a cross.
numbers were small and follow up limited, the actuarial survival to one year was 55% (Cutler-Ederer method). There were five deaths. The first (patient 4) occurred at 69 days from chronic pulmonary rejection associated with respiratory infections caused by *Pseudomonas aeruginosa, Mycoplasma pneumoniae*, and adenovirus. Postmortem examination of the lungs revealed obliterative bronchiolitis. The second death (patient 7) occurred at 36 hours postoperatively. This appeared to be associated with donor/recipient lung size mismatch. The smaller implanted lungs became overinflated which produced increased pulmonary vascular resistance and subsequent right heart failure. Patients 5 and 8 died at 291 and 242 days postoperatively respectively. Obliterative bronchiolitis was diagnosed in both at postmortem examination. The final death was patient 10 as a result of mediastinitis and the development of an aortic pseudoaneurysm.

Early acute pulmonary rejection, diagnosed either clinically or histologically, occurred in two patients (patients 2 and 11) during the first week, and in the surviving patients during the second week after transplantation. All were treated with intravenous boluses of methylprednisolone and showed resolution of clinical and radiological signs. Subsequent rejection episodes diagnosed histologically by transbronchial biopsy specimens were frequent. There was a mean of 5.7 episodes of rejection per patient in the seven surviving the first six months after transplant (fig 2).

Excluding the early postoperative period when antimicrobial prophylaxis was given, a total of 14 microscopically proved and treated pulmonary infective complications, including tracheobronchitis in 12 and pneumonia in two, occurred in those seven patients surviving the first six months. These often accompanied rejection episodes (fig 2). This represented a mean incidence of 2.0 respiratory infections per patient in the first six months. The most common pathogen isolated was *P aeruginosa* (9/14) and *Staphylococcus aureus* and group A β haemolytic streptococci were also cultured. Adenovirus and *M pneumoniae* were implicated on serological evidence (fourfold rise in titres) in producing a severe pneumonitis in patient 4.

Other infective events included herpes simplex labialis in three patients. Chronic mediastinitis due to *P aeruginosa* associated with the development of an aortic pseudoaneurysm occurred in patient 10. Death resulted from neurological complications after resection of the aortic pseudoaneurysm. Cellulitis of the dorsum of the foot subsequent to an infected toe also developed in this patient.

Other early complications included meconium ileus equivalent, defined as subacute gastrointestinal obstruction due to inspissated faeces, which occurred in three patients (patients 2, 3, 4). This responded to medical treatment with oral acetylcysteine, aperients, and Gastrografin enemas (Schering). In the later patients in the series, prophylactic treatment with acetylcysteine was started in the perioperative period when bowel sounds were audible and continued until a regular bowel pattern was established. Pancreatitis occurred in one patient (patient 8) on day 3. This was successfully managed conservatively by gut rest and the implementation of parenteral nutrition.

Later problems included the development of diabetes mellitus subsequent to corticosteroid treatment. This occurred transiently in two patients (patients 1 and 5) and four (patients 2, 4, 8, 10) required long term treatment with insulin.

Tracheal stenosis developed in two patients.

---

*Figure 2. Number of episodes of pulmonary rejection and pulmonary infection in those cystic fibrosis patients surviving the first six months after heart-lung transplantation.*

*Figure 3. Mean (SD) FEV% in patients with cystic fibrosis patients, preoperatively and to 12 months after heart-lung transplantation. The number of patients in each epoch is indicated.*

*Figure 4. Forced vital capacity of patient 2 after heart-lung transplantation. Note the increase to recipient predicted values (line 1) rather than those predicted for the donor (line 2).*
Heart-lung transplantation for cystic fibrosis. 2: Outcome

patients 5 and 8). This developed just below the tracheal anastomosis at six and three months respectively. They were successfully managed by tracheal dilatation and insertion of silastic endotracheal stents. Systemic hypertension requiring treatment developed in only one patient (patient 8) and was successfully controlled with the calcium channel blocker, nifedipine (1 mg/kg/day). Lung function after transplant, measured by FEV1%, showed an increase in all patients who survived beyond hospital discharge, with a mean of 73-5% at 6 months (fig 3). Lung function after transplant, measured by forced vital capacity, appeared to follow that predicted for the recipient rather than the donor (fig 4).

Discussion

The early postoperative results in our series were encouraging, with only two patients not surviving to hospital discharge. Excellent early graft function in all but one patient (patient 7) affirmed our donor selection and procurement methodology. Of more concern was the morbidity and mortality specifically associated with the high incidence of pulmonary rejection with or without associated respiratory infection. This appeared to lead to definite obliterative bronchiolitis in three patients (4, 5, and 8, which was confirmed at postmortem examination) and chronic rejection changes in two patients (1 and 2) despite immunosuppression. The increased episodes of rejection do not appear related to the pre-existing diagnosis, as adult recipients of heart-lung transplants with cystic fibrosis do not reject any more frequently than adult patients without cystic fibrosis.

Although Bailey et al have noted less rejection in young infants receiving orthotopic cardiac transplants, we have noted an increased incidence in the child receiving a combined heart-lung graft compared with the adult, using a similar immunosuppression and monitoring regime. This discrepancy remains unexplained.

Pulmonary infection often coexisted with rejection though did occur de novo. The high percentage of Pseudomonas spp isolated reflects the prevalence of this organism in patients with cystic fibrosis. The source appears to be the colonised native upper airways. Although often cultured from the respiratory tract, the majority of infections involved the tracheobronchial tree rather than the lung parenchyma. In the adult series the incidence of true pneumonia with this organism is not significantly different between recipients of heart-lung transplants with and without cystic fibrosis.

The introduction of bronchoscopy, both flexible fibreoptic and rigid, bronchoalveolar lavage, and transbronchial biopsy in the management of our paediatric patients has been of great value in assessing pulmonary infection and rejection. However, these procedures are more hazardous in children and we therefore routinely use general anaesthesia and fluoroscopy to decrease the risk of complications (for example, hypoxia subsequent to a compromised airway and pneumothorax).

Pancreatitis was a clinical problem in patient 8. No infective cause was found and he responded to conservative medical management. This has been previously described occurring in adult cardiac and cardiopulmonary recipients. Considering the degree of pancreatic involvement in cystic fibrosis, this is surprising that more cases were not seen. This is particularly true in view of the high incidence of diabetes mellitus observed (6/11). This latter problem is a well known complication of cystic fibrosis, but was undoubtedly exacerbated by the high dose corticosteroids used for treatment of graft rejection.

There was a higher incidence of tracheal anastomotic stenosis (two of 11 patients 18%), then observed in the adult series, despite identical operating techniques. This may be explained by a less well developed, coronary-bronchial collateral circulation in the younger patient. Other paediatric series have experienced an increased incidence of this complication. It was of interest to note that both affected children rapidly succumbed to obliterative bronchiolitis after repeated episodes of acute allograft rejection.

Although our short term survival figures for heart-lung transplantation in cystic fibrosis compared with the current worldwide one year survival of 61%, they remain lower than the Papworth Hospital adult series. This may be related to a greater propensity to severe graft rejection in the child, though our numbers remain too small to make confident statistical comparisons regarding this. Certainly, it seems greater control of graft rejection with improved methods of immunosuppression are required to improve the overall longer term results.

We would like to thank Mr P Goldstraw, Brompton Hospital, London, for treating our patients with tracheal stenosis and special thanks to Miss P Smith and Miss L Stanger for preparation of the manuscript.

Commentary

These two papers from the Hospital for Sick Children and Papworth Hospital give a very clear account of their meritorious multidisciplinary team approach to the assessment of children with cystic fibrosis being considered for heart-lung transplantation. The survival of 55%, three months to three years after transplantation, is disappointing compared with the adult figures from Papworth, presented recently, of 78% at one year and 66% at 3 years (Cystic Fibrosis Research Trust Meeting, 1991). My experience at the Brompton Hospital was broadly similar to that of the Hospital for Sick Children, though more of my patients were not accepted on the programme and consequently a large percentage on the active waiting list were actually transplanted.

Whitehead and colleagues have attempted to define the indices of poor short term survival based on deaths in their cystic fibrosis clinic over a 10 year period but fail to indicate how many patients with similar prognostic features survived for more than two years. Furthermore, they do not define the features which indicate that it is too late to consider heart-lung transplantation. The mean time to death of their 10 patients who died awaiting transplantation was only 3-7 months, suggesting that selection should be based not only on a maximum projected survival of two years without heart-lung transplantation but also a minimum of three months. This might avoid some of the inevitable anguish, recrimination, and guilt suffered by the families of those who die waiting.

From the combined figures from the Brompton Hospital and Hospital for Sick Children only a sixth of the referrals had truly benefited from heart-lung transplantation, half had died either before or after the procedure and the remainder were still waiting. These are the harsh realities which paediatricians must now present to their patients with cystic fibrosis and families, but there are additional less well defined issues which must also be considered.

The psychosocial problems which occur in those families drawn into the transplantation programme are immense. For some the hope generated has a very positive effect but for many the whole procedure is a nightmare which ends in disaster. Heart-lung transplantation is not the miraculous cure imagined by many. It merely replaces lungs diseased by cystic fibrosis with a foreign heart and lungs at perpetual risk of rejection and an inevitable iatrogenic immunodeficiency. Even if the results improve substantially, there will never be enough hearts and lungs available for all but a minority of patients. Indeed if all patients with cystic fibrosis deemed suitable for heart-lung transplantation were referred to transplant centres, in addition to the vast number of patients with other heart and lung diseases, then the percentage achieving benefit would be tiny.

The spectre of heart-lung transplantation has already affected our practice in cystic fibrosis clinics, forestalling the well established use of pleurectomy for pneumothoraces, steroids in end stage disease, and effective terminal care. Such changes must be resisted at all costs and heart-lung transplantation should not deter continuing effort to control cystic fibrosis medically.

Can the benefit from the massive investment in heart-lung transplantation for a lucky minority really offset the suffering of the majority? This issue is far from resolution and open discussion in the journals is essential to allow us all to reach an informed opinion.